Qiming Venture cuts China fund target by 25% to $600 million

Qiming Venture cuts China fund target by 25% to $600 million

Qiming Venture Partners has announced a significant reduction in its target for a new China-focused fund. The venture capital firm has cut its target by 25%, bringing the new fund's size down to $600 million. This adjustment comes as the firm continues to navigate the evolving investment landscape and strategic focus.

Since its establishment in 2006, Qiming Venture Partners has been a prominent player in the venture capital and private equity space, managing a total of $9.5 billion in capital across eleven US Dollar funds and seven RMB funds [1]. The firm's portfolio includes over 580 fast-growing and innovative companies, with over 210 achieving exits through IPOs or M&As, and over 80 becoming unicorns or super unicorns.

The decision to reduce the China fund target by 25% reflects Qiming's strategic approach to investment, focusing on sectors such as technology and healthcare. The firm's portfolio companies have demonstrated significant growth and innovation, with notable achievements including the development of advanced technologies and innovative medical solutions.

Qiming Venture Partners' strategic focus on technology and healthcare continues to position it as a leader in these sectors. The firm's portfolio includes companies like TandemAI, which has launched TandemViz 3.5, an upgrade that enhances molecular design workflows with advanced structure prediction and intelligent compound generation [2].

The firm's commitment to innovation is evident in its portfolio companies' achievements. For instance, Asieris Pharmaceuticals, a portfolio company, has demonstrated positive preliminary results for its oral drug APL-1401 in a Phase 1b clinical trial for the treatment of ulcerative colitis [3]. Additionally, DeepWay BEV Truck has made its international debut at the 2025 EROAD Fleet Manager's Day, showcasing its flagship smart electric heavy truck [4].

Qiming Venture Partners' strategic adjustment in the China fund target reflects its ongoing commitment to value-driven investment and innovation. The firm's focus on technology and healthcare sectors, along with its track record of successful investments, positions it as a key player in the venture capital landscape.

References:
[1] https://hk.linkedin.com/company/qiming-venture-partners
[2] https://www.qimingvc.com
[3] https://www.qimingvc.com/asieris-pharmaceuticals
[4] https://www.qimingvc.com/deepway-bev-truck